RIG 200
RIG 200 is an S-nitrosothiol nitric oxide (NO) donor. RIG 200 releases NO through decomposition, activating guanylate cyclase (sGCM) in vascular smooth muscle cells, increasing cGMP levels, and leading to vasodilation. RIG 200 significantly inhibits Collagen -induced platelet aggregation in platelet-rich plasma (PRP). RIG 200 may be used in research on antithrombus[1][2][3].
Product Specifications
CAS Number
202656-49-3
UNSPSC
12352005
Target
Guanylate Cyclase; NO Synthase
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Smiles
CC(O[C@@H]1[C@H]([C@@H](O[C@H](COC(C)=O)[C@H]1OC(C)=O)OC(C)=O)NC([C@H](NC(C)=O)C(C)(C)SN=O)=O)=O
Molecular Formula
C21H31N3O12S
Molecular Weight
549.55
References & Citations
[1]Megson IL, et al. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br J Pharmacol. 2000 Dec;131 (7) :1391-8. |[2]Sogo N, et al. S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol. 2000 Nov;131 (6) :1236-44.|[3]Sogo N, et al. A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. Clin Pharmacol Ther. 2000 Jul;68 (1) :75-81.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
F2402 96 Tests
Na (+) /H (+) exchange regulatory coFactor NHE-RF2 (SLC9A3R2) Human ELISA Kit
Sign In for Pricing
View Details 